2 minutes reading time (374 words)

Palbociclib and Cetuximab Show Promise in Head and Neck Cancer

Head and neck cancer.

Many cases of head and neck squamous cell carcinoma (HNSCC) are caused by human papillomavirus (HPV); however, HNSCCs can be caused by a variety of factors, including p16INK4A inactivation (an inhibitor of cyclin-dependent kinase 4A) and overexpression of the oncogene cyclin D1. This results in the stimulation of cyclin-dependent kinase 4 and 6 (CDK4/6). Overexpression of cyclin D1 can also cause resistance to epidermal growth factor receptor (EGFR) inhibitors. To overcome this resistance, researchers conducted a study to determine if patients with recurrent or metastatic HNSCC could achieve an objective response to the CDK4/6 inhibitor and EGFR inhibitor combination of palbociclib and cetuximab.

For this study (NCT02101034), published in The Lancet Oncology, 62 patients were enrolled. The patients were split into two groups: 30 patients in group 1 who had platinum-resistant HNSCC, and 32 patients in group 2 who had cetuximab-resistant, HPV-unrelated HNSCC. To be eligible, patients had to have measurable disease according to Response Evaluation Criteria in Solid Tumors, version 1.1, and an Eastern Cooperative Oncology Group performance status of 0 to 2. In addition, participants had to be 18 years old or older, and have experienced disease progression on platinum but be cetuximab-naive (group 1) or have experienced disease progression on cetuximab (group 2).

All of the patients were administered 125 mg per day of oral palbociclib on days 1 through 21 and 400 mg/m2 intravenous cetuximab on cycle one, day one, then progressed to 250 mg/m2 once per week. Medication cycles lasted 28 days.

The results revealed that 39% of patients in group 1 achieved an objective response. In group 2, 19% of patients achieved an objective response. Grade 3/4 neutropenia was the most common treatment-related adverse event associated with taking palbociclib.

The study authors conclude, "In patients with platinum-resistant or cetuximab-resistant HPV-unrelated HNSCC, palbociclib and cetuximab results in promising activity outcomes. Further studies of CDK4/6 inhibitors are warranted in HPV-unrelated HNSCC."

For More Information

Adkins D, Ley J, Neupane P, et al (2019). Palbociclib and cetuximab in platinum-resistant and in cetuximab-resistant human papillomavirus-unrelated head and neck cancer: a multicenter, multigroup, phase 2 trial. Lancet Oncol. [Epub ahead of print] DOI:10.1016/S1470-2045(19)30405-X

Image Credit: BruceBlaus. Courtesy of Wikimedia Commons. Licensed under CC-BY-SA-4.0.


JMJD6 Identified as a Neuroblastoma Tumorigenic Fa...
Nivolumab: Five-Year Survival for Melanoma, RCC, a...

Related Posts

By accepting you will be accessing a service provided by a third-party external to https://www.i3health.us/

Copyright © 2020 i3 Health. All rights reserved.